Automate Your Wheel Strategy on CLDX
With Tiblio's Option Bot, you can configure your own wheel strategy including CLDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLDX
- Rev/Share 0.1139
- Book/Share 10.5898
- PB 2.0756
- Debt/Equity 0.0049
- CurrentRatio 21.6677
- ROIC -0.3064
- MktCap 1459344516.0
- FreeCF/Share -2.5899
- PFCF -8.4883
- PE -8.1582
- Debt/Assets 0.0046
- DivYield 0
- ROE -0.2346
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CLDX | Canaccord Genuity | -- | Buy | -- | $64 | April 28, 2025 |
| Initiation | CLDX | Morgan Stanley | -- | Overweight | -- | $46 | March 20, 2025 |
| Initiation | CLDX | UBS | -- | Buy | -- | $44 | Feb. 13, 2025 |
| Initiation | CLDX | Citigroup | -- | Buy | -- | $70 | Oct. 7, 2024 |
| Initiation | CLDX | Goldman | -- | Neutral | -- | $45 | Sept. 30, 2024 |
| Downgrade | CLDX | Wolfe Research | Outperform | Peer Perform | -- | -- | Sept. 27, 2024 |
News
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors.
Read More
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.57 per share a year ago.
Read More
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
HAMPTON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2024 and provided a corporate update.
Read More
About Celldex Therapeutics, Inc. (CLDX)
- IPO Date 1986-05-15
- Website https://www.celldex.com
- Industry Biotechnology
- CEO Anthony S. Marucci
- Employees 186